• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5071899)   Today's Articles (92)
For: Rhodes NJ, Liu J, McLaughlin MM, Qi C, Scheetz MH. Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC. Diagn Microbiol Infect Dis 2015;82:165-71. [PMID: 25801780 DOI: 10.1016/j.diagmicrobio.2015.03.005] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2014] [Revised: 02/26/2015] [Accepted: 03/03/2015] [Indexed: 11/29/2022]
Number Cited by Other Article(s)
1
Pais GM, Chang J, Barreto EF, Stitt G, Downes KJ, Alshaer MH, Lesnicki E, Panchal V, Bruzzone M, Bumanglag AV, Burke SN, Scheetz MH. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet 2022;61:929-953. [PMID: 35764774 PMCID: PMC9345683 DOI: 10.1007/s40262-022-01137-y] [Citation(s) in RCA: 43] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/02/2022] [Indexed: 11/28/2022]
2
β-lactam dosing strategies: Think before you push. Int J Antimicrob Agents 2020;56:106151. [PMID: 32882430 DOI: 10.1016/j.ijantimicag.2020.106151] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Revised: 08/12/2020] [Accepted: 08/22/2020] [Indexed: 12/12/2022]
3
Fluoroquinolone Versus Nonfluoroquinolone Treatment of Bloodstream Infections Caused by Chromosomally Mediated AmpC-Producing Enterobacteriaceae. Antibiotics (Basel) 2020;9:antibiotics9060331. [PMID: 32560457 PMCID: PMC7345702 DOI: 10.3390/antibiotics9060331] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 06/09/2020] [Accepted: 06/16/2020] [Indexed: 11/17/2022]  Open
4
Liu J, Pais GM, Avedissian SN, Gilchrist A, Lee A, Rhodes NJ, Hauser AR, Scheetz MH. Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational In Vivo Rat Model. Antimicrob Agents Chemother 2020;64:e02300-19. [PMID: 32071049 PMCID: PMC7179599 DOI: 10.1128/aac.02300-19] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Accepted: 02/12/2020] [Indexed: 12/24/2022]  Open
5
Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. Clin Pharmacokinet 2020;59:1027-1036. [PMID: 32140940 PMCID: PMC7222999 DOI: 10.1007/s40262-020-00873-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
6
Foong KS, Carlson AL, Munigala S, Burnham CAD, Warren DK. Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia. Open Forum Infect Dis 2019;6:ofz341. [PMID: 31660387 PMCID: PMC6735685 DOI: 10.1093/ofid/ofz341] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 07/17/2019] [Indexed: 11/14/2022]  Open
7
A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime. mSphere 2019;4:4/1/e00595-18. [PMID: 30700511 PMCID: PMC6354808 DOI: 10.1128/msphere.00595-18] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]  Open
8
Bader JC, Lakota EA, Andes DR, Rubino CM, Ambrose PG, Bhavnani SM. Time for Precision: A World Without Susceptibility Breakpoints. Open Forum Infect Dis 2018;5:ofy282. [PMID: 30581880 PMCID: PMC6297858 DOI: 10.1093/ofid/ofy282] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Accepted: 10/29/2018] [Indexed: 12/16/2022]  Open
9
Miglis C, Rhodes NJ, Liu J, Gener J, Hang E, Scheetz MH. Quantifying the importance of active antimicrobial therapy among patients with Gram-negative bloodstream infections: Cefepime as a representative agent. Int J Antimicrob Agents 2018;53:95-97. [PMID: 30315921 DOI: 10.1016/j.ijantimicag.2018.10.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Revised: 10/02/2018] [Accepted: 10/06/2018] [Indexed: 11/28/2022]
10
The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination. Antimicrob Agents Chemother 2018;62:AAC.00433-18. [PMID: 29784837 DOI: 10.1128/aac.00433-18] [Citation(s) in RCA: 64] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 05/16/2018] [Indexed: 01/03/2023]  Open
11
Rhodes NJ, Grove ME, Kiel PJ, O'Donnell JN, Whited LK, Rose DT, Jones DR, Scheetz MH. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens. Int J Antimicrob Agents 2017;50:482-486. [DOI: 10.1016/j.ijantimicag.2017.04.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 03/30/2017] [Accepted: 04/05/2017] [Indexed: 11/16/2022]
12
Miglis C, Rhodes NJ, Kuti JL, Nicolau DP, Van Wart SA, Scheetz MH. Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window. Int J Antimicrob Agents 2017;50:487-490. [PMID: 28668683 DOI: 10.1016/j.ijantimicag.2017.04.023] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2016] [Revised: 04/04/2017] [Accepted: 04/06/2017] [Indexed: 01/24/2023]
13
Ratliff AR, Gentry CA, Williams RJ. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime. Diagn Microbiol Infect Dis 2017;87:376-381. [PMID: 28087171 DOI: 10.1016/j.diagmicrobio.2016.12.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2016] [Revised: 12/29/2016] [Accepted: 12/30/2016] [Indexed: 11/17/2022]
14
Arizpe A, Reveles KR, Patel SD, Aitken SL. Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria. Curr Infect Dis Rep 2016;18:39. [PMID: 27743202 PMCID: PMC11801173 DOI: 10.1007/s11908-016-0552-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
15
Sethaphanich N, Santanirand P, Rattanasiri S, Techasaensiri C, Chaisavaneeyakorn S, Apiwattanakul N. Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options. Pediatr Int 2016;58:338-46. [PMID: 26513341 DOI: 10.1111/ped.12845] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Revised: 09/02/2015] [Accepted: 10/21/2015] [Indexed: 11/26/2022]
16
Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs. J Clin Microbiol 2016;54:840-4. [PMID: 26791363 DOI: 10.1128/jcm.02424-15] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
17
Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. Antimicrob Agents Chemother 2015;60:1401-10. [PMID: 26666929 DOI: 10.1128/aac.01956-15] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Accepted: 12/07/2015] [Indexed: 01/06/2023]  Open
18
Tree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the Horse. Antimicrob Agents Chemother 2015;60:838-44. [PMID: 26596934 DOI: 10.1128/aac.01564-15] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2015] [Accepted: 11/15/2015] [Indexed: 11/20/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA